Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 767551 for post-exposure prevention of SARS-CoV-2 infection in household contacts
2021-000408-39Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BI 767551 with Placebo (2 arms). Primary endpoint: Symptomatic SARS-CoV-2 infection by Week 4. Started May 2021; status: terminated.
02
Drugs
lomtegovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000408-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000408-39.